ICICI Securities Ltd | Retail Equity Research Revenues grew 34% YoY to | 2079 crore (I-direct estimate: | 2240 crore) mainly due to consolidation of Triad Pharmacy business. The pharma business grew 44% YoY to | 1181 crore (I-direct estimate: | 1268 crore). Excluding Triad, the pharma business grew ~9% YoY EBITDA margins contracted 46 bps YoY to 21.1% (I-direct estimate: 20.3%) mainly due to consolidation of pharmacy business. EBITDA grew 29.6% YoY to | 437.6 crore (I-direct estimates: | 453.7 crore)...